Pharmaceutical companies including Abbvie, Johnson & Johnson, Bristol Myers Squibb, Takeda, and Astex have collaborated through the AI Structural Biology network to share proprietary protein-ligand structural data to train advanced large language models for drug discovery. This unprecedented data pooling creates a rich chemical and structural resource aimed at boosting AI capabilities in medicinal chemistry. Separately, researchers at Integra Therapeutics, UPF, and CRG have demonstrated generative AI's superiority in designing synthetic proteins with enhanced genome editing performance, signaling a new frontier in computational protein engineering with broad therapeutic implications.